English 
The planet can no longer treat all people alike. Universal healthcare system is no longer a viable option, particularly in Japan where the aging populace is pushing the necessity of smarter and more accurate medical care. Personalized medicine is a panacea, adjusting medications to every patient’s distinct genetic and biological characteristic.
Japan is very well placed to navigate this transformation. The country is creating a mix of biology and computation that few other places in the world can do, with large-scale national genomic databases and increasing proficiency in generative AI. AMED is at the center of this push, funding projects that blend multiple research areas, from drug development to regenerative medicine. In 2025, AMED’s programs included large calls like SATREPS, symposia on topics such as Proteostasis, and cross-ministerial initiatives that help move discoveries from the lab to real-world applications.
This article will trace Japan’s path from genomic infrastructure to AI-driven solutions, explore clinical successes, and examine the governance and ethical frameworks that make this revolution trustworthy.
こちらもお読みください： Should IT leaders invest more in AI automation or workforce reskilling
The Genomic Foundation of Japan’s Multi-Omics Infrastructure
Japan’s push toward personalized medicine begins with the backbone of its healthcare innovation: deep, high-quality genomic data. At the center of this effort is BioBank Japan, a national treasure for multi-omics research. As of July 2025, BBJ houses around 270,000 patients’ DNA samples, covering 51 diseases. The scale is staggering, with approximately 800,000 DNA tubes and 1.7 million serum tubes carefully catalogued for research use. Beyond quantity, the quality is world-class; the biobank holds ISO certifications for both quality management and information security, ensuring that every sample is reliable and protected.
The real power comes from the richness of multi-omics data. BBJ not only keeps DNA samples but also does whole-genome sequencing for 16,000 patients and provides SNP data for all 270,000. Such a thoroughness makes it possible for researchers as well as generative AI models to find out the patterns, estimate the disease risks and even come up with the potential intervention not only quicker but also in a more efficient manner than traditional methods. The linking of CHEK2 to 23 cancer types is just one of the regular updates that have shown how the current disease-gene associations are already influencing clinical research.
The genomic field considered turning the huge volumes of データ into actionable insights the biggest challenge for many years. A lot of genetic information was available but the use of tools for the analyzation and interpretation of data was not developed enough, thus leaving a great part of its potential untapped. Today, multi-omics integration combined with AI-powered analysis is closing that gap. Japan isn’t just collecting data; it is transforming it into a dynamic engine for personalized healthcare. With this foundation, clinicians and researchers can translate complex genomic information into precise, patient-specific interventions that have the potential to truly change care.
Generative AI as the Computational Catalyst
Generative AI is changing the game for personalized medicine. Generative AI, in contrast to conventional machine learning, is not limited only to prediction or classification but rather it is able to come up with new solutions. In the field of biology, this translates to drug designing, treatment planning, or even individualized patient interventions. Such revelations are difficult to detect through the old methods, particularly when the data sources are complex like genomes, proteins and metabolites.
Japan has the tech to make this real. AIST’s ABCI 3.0 supercomputer went fully live in January 2025. It comprises 6,128 エヌビディア H200 GPUs and attains 6.22 exaflops at precision level of half. The hard drive capacity as well as the read/write speeds are twice as fast as those of the predecessor. The immense computing power associated with AI helps in processing huge datasets in mere seconds and thereby getting insights from raw data which are useful to the academics.
One major use is drug discovery. AI looks at a patient’s mutation profile and helps find the best targets, whether small molecules or biologics. Astellas Pharma puts this into action. The partnership with Mitsubishi Research Institute for the support of pharma startups happened in 2025. As an example, the Future Innovator Prize made it possible for companies such as DeepSeq.AI and Serna Bio to get laboratory access, mentorship, and assistance to transform AI-based concepts into real life applications.
Another area is clinical decision support. AI trained on multi-omics data can read complex patient records almost instantly and suggest likely treatment paths. Doctors get faster insights, and patients get care that’s more precise.
Generative AI isn’t just theory anymore. With strong compute, rich data, and industry partnerships, Japan is turning it into a real tool that can help clinicians deliver smarter, patient-focused medicine.
Clinical Translation Real-World Experience and Precision
Personalized medicine only matters when it works in the clinic. Take pharmacogenomics. AI looks at a patient’s genome and predicts how they will respond to a medicine. This translates into less adverse reactions and therefore safer treatment, which is an important issue for the elderly population of Japan. Physicians can alter the dosages beforehand rather than wait to see what will happen. This transition from reactive to proactive prescribing is, in fact, very much altering the delivery of the healthcare system.
AI is making a real difference in cancer treatment, which is another area to mention. Tumors have the genetic information that indicates what the best therapies would be. AI is capable of handling this intricate data very quickly and then pairing the patients with the right immunotherapy or targeted therapy. Along with corresponding the Japanese-made treatment to the effort, this provides patients with options that are tailored precisely to their genetic profiles.
But AI isn’t magic. Doctors need to trust it. Explainable AI, or XAI, shows how the system reaches its conclusions so clinicians can make informed decisions without second-guessing. Training programs are helping doctors work alongside AI instead of feeling replaced by it.
By combining pharmacogenomics, AI-guided cancer therapy, and a trusted human-AI interface, Japan is turning data into care that actually fits the patient. Personalized medicine is no longer a promise. It’s happening in clinics, helping people get treatments made for them, not the average patient.
Governance, Ethics, and the Trust Mandate
Personalized medicine isn’t just about data and AI. It’s also about trust. Japan has built strong safeguards to make sure patient information stays secure. Strict data protection frameworks, similar to Europe’s GDPR but tailored for local needs, protect genomic and AI-processed data. This ensures sensitive health information doesn’t fall into the wrong hands.
Regulators are also adapting to keep pace with technology. The PMDA is modernizing approval pathways to handle AI-driven diagnostics and “living” algorithms that learn and improve over time. Japan’s approach is flexible, aiming to encourage innovation while keeping safety front and center.
METI is playing a key role too. The company’s initiative, the Generative AI Accelerator Challenge, which is known as ジェニアック, is a venture that encourages the development of AI platforms and models by offering computing resources, pilot data, and collaboration opportunities. The 2025 Action Plan is a continuation of this trend, it points to the area of generative AI, quantum computing, and strategic tech domains. The AI Guidelines for Business Ver 1.0 designed to direct companies on the responsible implementation of AI have been released earlier. These measures simultaneously promote innovation and control, thus, making AI-powered personalized medicine safer, more effective, and more trustworthy for patients.
The Path to Global Leadership
Japan is actually putting personalized medicine into practice. Doctors are spotting problems early. They’re adjusting treatments to fit each person and skipping guesswork whenever they can. This isn’t something way off in the future. It’s happening in clinics right now. Cancer care, drug response, and complex health data are being handled smarter and faster thanks to AI and rich genomic information. Japan’s approach mixes technology, ethics, and real-world application in a way other countries can learn from. Care is safer, more precise, and built for the individual. It’s a bold move that sets a standard the world is watching.
日本語